pyruvate
Small moleculeexperimental
Sodium pyruvate is a salt of the conjugate anion form of pyruvic acid, known as pyruvate. It is commonly added to cell culture media as an additional source of energy, but may also have protective effects against hydrogen peroxide. This was reported by Giandomenico et al. and has been confirmed by several independent groups. — Wikipedia
Clinical trial activity
24 trials · 24 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
4
Phase 4
1
Earliest trial started Apr 1, 2004 (NCT00605930)
Timeline
Indications
Approved for
Studied for
- Asthma · Phase 1/Phase 2
- Brain Neoplasms · Phase 1
- Coronary Disease · Phase 2
- COVID-19 · Phase 2/Phase 3
- Cystic Fibrosis · Phase 1
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 2
- Heart Valve Diseases · Phase 2
- Hypertension · Phase 1
- Hypertrophy · Phase 1
- Idiopathic Pulmonary Fibrosis · Phase 3
- Influenza, Human · Phase 2/Phase 3
- Myocardial Infarction · Phase 2
- Prostatic Neoplasms · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Shock, Cardiogenic · Phase 2
- Warts · Phase 4
Mechanism of action
- Pyruvate kinase isozymes R/LSUBSTRATE
PKLR substrate
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)C(=O)O- Mol. weight
- 88.06 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSodium pyruvate ↗
- ChEMBLCHEMBL1162144 ↗
- WikipediaPyruvic acid ↗
Also known as
- 13c-lactate
- 2-ketopropionic acid
- 2-ketopropionic acid
- 2-oxopropanoic acid
- 2-oxopropanoic acid
- 2-oxopropanoic acid ethyl ester
- 2-oxopropanoic acid ethyl ester
- 2-oxopropansäure
- 2-oxopropansäure
- 2-oxopropionic acid ethyl ester
- 2-oxopropionic acid ethyl ester
- 2-oxopropionsäure
- 2-oxopropionsäure
- acetylformic acid
- acetylformic acid
- acide pyruvique
- acide pyruvique
- a-ketopropionic acid
- a-ketopropionic acid
- alpha-ketopropionic acid
- alpha-ketopropionic acid
- brenztraubensäure
- brenztraubensäure
- bts
- bts
- dichloroacetate
- ethyl 2-oxopropanoate
- ethyl 2-oxopropanoate
- ethyl 2-oxopropionate
- ethyl 2-oxopropionate
- ethyl methylglyoxylate
- ethyl methylglyoxylate
- ethyl pyruvate
- ethyl pyruvate
- ethyl pyruvate
- pyroracemic acid
- pyroracemic acid
- pyruvate
- pyruvate
- pyruvic acid
- pyruvic acid
- pyruvic acid
- pyruvic acid ethyl ester
- pyruvic acid ethyl ester
- pyruvic acid, ethyl ester
- pyruvic acid, ethyl ester
- sodium pyruvate
- sodium pyruvate
- α-ketopropionic acid
- α-ketopropionic acid
- α-oxopropionsäure
- α-oxopropionsäure
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06037408 | Phase 3 | Aug 15, 2023 | Cellular Sciences, Family First Medical Research Center |
| NCT04871815 | Phase 2/Phase 3 (Phase 3) | Apr 27, 2021 | Cellular Sciences, Dynamic DNA Labs, Family First Medical Research Center, People's Liberation Army of China, Trinity Health Care |
| NCT04824365 | Phase 2/Phase 3 (Phase 3) | Apr 12, 2021 | Cellular Sciences, Dynamic DNA Labs, Family First Medical Research Center, People's Liberation Army of China, Trinity Health Care |
| NCT04623502 | N/A | Sep 30, 2019 | Howard Hughes Medical Institute, National Cancer Institute (NCI), The University of Texas, Dallas |
| NCT03797469 | N/A | Apr 15, 2019 | Columbia University |
| NCT02947373 | Phase 1 | Oct 1, 2016 | University of California, San Francisco |
| NCT02911467 | Phase 1 | Jul 1, 2016 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of California, San Francisco |
| NCT02647983 | Phase 1 | Apr 1, 2016 | University of Toronto |
| NCT02648009 | Phase 1 | Apr 1, 2016 | University of Toronto |
| NCT02913131 | Phase 1 | Dec 1, 2015 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of California, San Francisco |
| NCT02526368 | Early Phase 1 (Phase 1) | Nov 1, 2015 | University of California, San Francisco |
| NCT02450201 | N/A | Jun 1, 2015 | University of California, San Francisco |
| NCT02421380 | N/A | Apr 1, 2015 | Cornell University |
| NCT02151630 | Phase 2/Phase 3 (Phase 3) | May 1, 2014 | Isfahan University |
| NCT01807702 | Phase 1 | Mar 1, 2013 | University of Florida |
| NCT01712295 | Phase 4 | Nov 1, 2011 | Grossman, Michael, D.P.M., Main Line Health |
| NCT01229618 | Phase 1 | Oct 1, 2010 | General Electric, University of California, San Francisco |
| NCT00604331 | Phase 2 | Aug 1, 2008 | University of Goettingen |
| NCT00308243 | Phase 1 | Mar 1, 2006 | Cellular Sciences, Emphycorp, University of Minnesota |
| NCT00332215 | Phase 1 | Feb 1, 2006 | Cellular Sciences, University of Minnesota |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellular Sciences | For profit | 6 | 3 | 3 | 2004 |
| University of California, San Francisco | Academic/Hospital | 6 | 6 | 2 | 2010 |
| Emphycorp | For profit | 3 | 3 | 2 | 2004 |
| Family First Medical Research Center | Academic/Hospital | 3 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2015 |
| Dynamic DNA Labs | Academic/Hospital | 2 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2015 |
| People's Liberation Army of China | Government | 2 | 0 | 1 | 2021 |
| Trinity Health Care | Academic/Hospital | 2 | 0 | 1 | 2021 |
| University of Minnesota | Academic/Hospital | 2 | 1 | 1 | 2006 |
| University of Toronto | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Critical Therapeutics | For profit | 1 | 1 | 1 | 2005 |
| General Electric | For profit | 1 | 0 | 1 | 2010 |
| Grossman, Michael, D.P.M. | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Howard Hughes Medical Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Isfahan University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Main Line Health | Academic/Hospital | 1 | 0 | 1 | 2011 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2019 |
24 organizations
Page 1 / 2